Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04526782 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ENCOrafenib With Binimetinib in bRAF NSCLC

Study acronym: ENCO-BRAF
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from Mar 2026 to Mar 2027v12
  2. Primary completion date changed from estimate of Jun 2025 to Jul 16, 2025v11
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 37 to 36 · Primary completion date: Dec 2024 to Jun 2025v10 Show 2 more changesShow less
    • Study sites: 37 to 36
    • Primary completion date: Dec 2024 to Jun 2025
  4. Primary completion date: Sep 2024 to Dec 2024 Site contacts updated at 2 of 37 sitesv9 Show 1 more changeShow less
    • Site contacts updated at 2 of 37 sites
  5. Primary completion date: Feb 2024 to Sep 2024 Study sites: 36 to 37v8 Show 1 more changeShow less
    • Study sites: 36 to 37
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 40 to 36v7
  2. Site details revised at 5 of 40 sites Eligibility criteria expanded, about 4 wordsv6 Show 1 more changeShow less
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv5
  4. Primary completion date: Sep 2022 to Feb 2024 Enrollment target: 144 to 119 · Study sites: 38 to 40 · Completion date: Mar 2025 to Mar 2026 · 4 morev4 Show 7 more changesShow less
    • Enrollment target: 144 to 119
    • Study sites: 38 to 40
    • Completion date: Mar 2025 to Mar 2026
    • Interventions: Binimetinib 15 MG (Drug), Docetaxel (Drug), Encorafenib 75 MG (Drug) to Binimetinib 15 MG (Drug), Encorafenib 75 MG (Drug)
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study arms: 3 to 2

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 2021 to Jan 19, 2021 · Site details revised at 38 of 38 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Jan 2021 to Jan 19, 2021
    • Site details revised at 38 of 38 sites
  6. Start date: Oct 2020 to Jan 2021 Enrollment target: 105 to 144 · Primary completion date: Jun 2022 to Sep 2022 · Completion date: Dec 2024 to Mar 2025v2 Show 3 more changesShow less
    • Enrollment target: 105 to 144
    • Primary completion date: Jun 2022 to Sep 2022
    • Completion date: Dec 2024 to Mar 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
Trial Details
NCT Number NCT04526782
Lead Sponsor Intergroupe Francophone de Cancerologie Thoracique
Conditions Non Small Cell Lung Cancer, BRAF V600E
Enrollment 119 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov